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Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at 
the time of publication and may evolve as the science develops.
The ongoing spread of COVID-19, also known as the novel 
coronavirus, has created significant concerns often leading to 
panic throughout the world as to its virulence and lethality. 
Regularly published media track newly infected patient rates and 
deaths further driving public panic, which invariably leads to 
people seeking information. As the use of social media continues 
to complement and augment the drive for free, open-access 
medical education, some have previously highlighted limitations 
posed by such a largely unregulated online venue.1 Previously, 
these opinions targeted much smaller populations, such as 
the push against electronic cigarettes after vaping-associated 
pulmonary injury was identified in 2019. With the increasing 
reach of COVID-19, however, concerns are not isolated to one 
section of society, but have instead permeated widely.
The potential for danger and patient harm is already evident, 
even as the United States and the world begin to grapple with 
large-scale lockdowns and nationwide efforts. The recent cascade 
of events surrounding the use of ibuprofen to treat fever in 
COVID-19 patients illustrates the power and deception of social 
media. On March 14, French Health Minister and physician 
Olivier Verán tweeted that “taking anti-inflammatory drugs 
(ibuprofen, cortisone … ) could be an aggravating factor of the 
infection.” Within 24 hours, over 43,000 individuals retweeted 
this advice despite little evidence to support this claim. In this 
short time, the World Health Organization’s (WHO) Christian 
Lindmeier, when asked about the tweet, quickly agreed that 
“we recommend using paracetamol, and do not use ibuprofen 
as a self-medication.”2 Major international news organizations 
immediately were abuzz with stories regarding the dangers of 
ibuprofen in COVID-19, “#ibuprofen” trended on social media, 
with many declaring it should not be used to treat fever at all. 
Twenty-four hours later, the official push against ibuprofen 
seemed to suddenly halt, and the WHO declared that it would 
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not recommend against the use of ibuprofen to treat medical 
conditions, including COVID-19 patients.3 
All of this concern was driven by a single letter published 
online in the Lancet on March 11 stating that the use of ibuprofen 
could theoretically increase the expression of angiotension-
converting enzyme 2 (ACE2) and facilitate COVID-19 
infection.4 It is important to note that this letter cited no studies 
to directly link ibuprofen use to ACE2 expression. Yet with a 
single tweet, we witnessed a major ripple effect against the use 
of a foundational antipyretic, and within 24 hours a whiplash 
back. But, there is no way to discern just how far the original 
statements reached, or whether the subsequent recalls undid the 
original misinformation entirely. While Dr. Verán’s statement 
was retweeted thousands of times, it remains unclear how far this 
information penetrated given that recalls rarely carry the impact 
that original statements do.
Similar social media turbulence has occurred with 
hydroxychloroquine and chloroquine, treatments for malaria 
and rheumatological diseases that have shown initial promise 
in small trials. This led to scarcity concerns that groups would 
try to purchase large quantities preemptively in case of approval 
by the  US Food and Drug Administration (FDA).5 Some states 
then went as far as to restrict prescription practices specifically 
out of concern for stockpiling these medications.6 This further 
demonstrates the effect that social media have on the practice 
of medicine even in the absence of science supporting these 
practices. Never have we witnessed such a large-scale concern 
over a generic medication in the setting of a health crisis.
While news organizations continue to search for up-to-the-
minute stories, and seek the most page views with sensational 
headlines, medical professionals must recognize our role in 
providing unsensational care. Efforts should be made to funnel 
questions to official organizations, such as the Centers for Disease 
Control and Prevention, the FDA, and local healthcare networks. 
Patients with concerns should seek evaluation and care in the 
clinical setting, not through social media. The turbulence of 
declarations and retractions makes the unease of this time all the 
worse. We must help centralize information by refraining from 
declarative diatribes and pushing unproven correlations. 
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